ethyl 4-amino-8-cyano-7-methyl-6-phenylpyrrolo[2,1-c][1,2,4]triazine-3-carboxylate

ID: ALA5268009

Max Phase: Preclinical

Molecular Formula: C17H15N5O2

Molecular Weight: 321.34

Names and Identifiers

Canonical SMILES:  CCOC(=O)c1nnc2c(C#N)c(C)c(-c3ccccc3)n2c1N

Standard InChI:  InChI=1S/C17H15N5O2/c1-3-24-17(23)13-15(19)22-14(11-7-5-4-6-8-11)10(2)12(9-18)16(22)21-20-13/h4-8H,3,19H2,1-2H3

Standard InChI Key:  CGGLARYCXFKJPW-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 26  0  0  0  0  0  0  0  0999 V2000
   -0.7376    0.8130    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0230    1.2253    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6888    0.8134    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.6888   -0.0116    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0212   -0.4235    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7376   -0.0154    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5255    1.0690    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5255   -0.2713    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0124    0.3989    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7398    1.8690    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9542    2.6691    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8407    0.3989    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7398   -1.0714    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0212   -1.2518    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4061   -0.4258    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4061   -1.2541    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.1234   -0.0116    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.1234    0.8165    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8407    1.2306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1543   -1.6573    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3688   -2.4547    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1690   -2.6691    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7529   -2.0875    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5433   -1.2867    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  2  2  0
  4  3  1  0
  5  4  2  0
  1  6  1  0
  6  5  1  0
  1  7  2  0
  6  8  1  0
  8  9  2  0
  9  7  1  0
  7 10  1  0
 10 11  3  0
  9 12  1  0
 13  8  1  0
  5 14  1  0
  4 15  1  0
 15 16  2  0
 15 17  1  0
 17 18  1  0
 18 19  1  0
 20 13  2  0
 21 20  1  0
 22 21  2  0
 23 22  1  0
 24 23  2  0
 13 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5268009

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 321.34

Molecular Weight (Monoisotopic): 321.1226

AlogP: 2.34

#Rotatable Bonds: 3

Polar Surface Area: 106.30

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: ┄

CX LogP: 2.17

CX LogD: 2.17

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.74

Np Likeness Score: -1.29

References

1. Cascioferro S, Parrino B, Spanò V, Carbone A, Montalbano A, Barraja P, Diana P, Cirrincione G..  (2017)  An overview on the recent developments of 1,2,4-triazine derivatives as anticancer compounds.,  142  [PMID:28851503] [10.1016/j.ejmech.2017.08.009]

Source

Source(1):

• Scientific Literature